BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35526247)

  • 1. Do high-mobility group box 1 gene polymorphisms affect the incidence of differentiation syndrome in acute promyelocytic leukemia?
    Hoseinzadeh G; Mohammadzadeh Z; Chahardouli B; Moghaddam KA; Mousavi SA; Omidkhoda A; Rostami S
    Mol Biol Rep; 2022 Jul; 49(7):5997-6004. PubMed ID: 35526247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
    Mohammadzadeh Z; Omidkhoda A; Chahardouli B; Hoseinzadeh G; Moghaddam KA; Mousavi SA; Rostami S
    BMC Cancer; 2021 Jan; 21(1):46. PubMed ID: 33422029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.
    Tang L; Chai W; Ye F; Yu Y; Cao L; Yang M; Xie M; Yang L
    Oncotarget; 2017 Apr; 8(16):27314-27327. PubMed ID: 28404891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
    Luesink M; Pennings JL; Wissink WM; Linssen PC; Muus P; Pfundt R; de Witte TJ; van der Reijden BA; Jansen JH
    Blood; 2009 Dec; 114(27):5512-21. PubMed ID: 19828696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome.
    Yamamoto de Almeida L; Pereira-Martins DA; Lima ASG; Baggio MS; de Araujo Koury LC; Lange AP; Bassi SC; Scheucher PS; Rego EM
    BMC Cancer; 2020 Aug; 20(1):821. PubMed ID: 32859169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute kidney failure in differentiation syndrome: a possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report].
    Di Micco L; Mirenghi F; Morelli E; De Simone E
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation syndrome in acute promyelocytic leukaemia.
    Stahl M; Tallman MS
    Br J Haematol; 2019 Oct; 187(2):157-162. PubMed ID: 31410848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.
    Tsumura Y; Yamada Y; Osumi T; Kato M; Terashima K; Shioda Y; Kiyotani C; Matsumoto K; Tomizawa D
    J Pediatr Hematol Oncol; 2020 May; 42(4):322-325. PubMed ID: 30807394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
    Eghtedar A; Rodriguez I; Kantarjian H; O'Brien S; Daver N; Garcia-Manero G; Ferrajoli A; Kadia T; Pierce S; Cortes J; Ravandi F
    Leuk Lymphoma; 2015 May; 56(5):1342-5. PubMed ID: 25120050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia.
    Dore AI; Santana-Lemos BA; Coser VM; Santos FL; Dalmazzo LF; Lima AS; Jacomo RH; Elias J; Falcão RP; Pereira WV; Rego EM
    J Leukoc Biol; 2007 Nov; 82(5):1340-3. PubMed ID: 17704297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
    Collinge E; Tigaud I; Balme B; Gerland LM; Sujobert P; Carlioz V; Salles G; Thomas X; Paubelle E
    Medicine (Baltimore); 2018 Feb; 97(8):e9657. PubMed ID: 29465554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.